Molecular Vision: Sangwan, Mol Vis 2022; 28:526-535. Table 5

Table 5. Evaluation of IL-4, IL-4R, IL-13a & IL-13b genotype association with the graded and ocular surface complications of chronic SJS/TEN patients.

Graded ocular complications (0–5)	IL-4 genotypes			IL-4R genotypes			IL-13a genotypes			IL-13b genotypes
Graded ocular complications (0–5)	CC (n=64)	CT (n=22)	TT (n=12)	AA (n=69)	AG (n=25)	GG (n=4)	CC (n=68)	CT (n=28)	TT (n=2)	GG (n=57)	GA (n=33)	AA (n=8)
POV (0–5)	3(0,5)	2(0,5)	3.5(0,5)	3(0,5)	3(0,5)	2.5(1,4)	3(0,5)	3(0,5)	3(3,3)	3(0,5)	3(0,5)	3.5(0,5)
CONC (0–5)	3(0,5)	2(0,5)	3.5(0,5)	3(0,5)	3(0,5)	2.5(1,4)	3(0,5)	3(0,5)	3(3,3)	3(0,5)	3(0,5)	3.5(0,5)
VASC (0–5)	2(0,5)	2(0,4)	2.5(0,5)	2(0,5)	2(0,5)	2.5(1,4)	2(0,5)	2.5(0,5)	1.5(1,2)	2(0,5)	2(0,5)	3(0,5)
KERT (0–5)	0(0,5)	0(0,4)	0.5(0,5)	0.0(0,5)	0.0(0,5)	0.0(0,4)	0(0,5)	0(0,5)	3.5(3,4)	0(0,5)	0(0,5)	2(0,5)
SPK (0–3)	0(0,3)	0(0,2)	0(0,2)	0.0(0,3)	0.0(0,2)	0.0(0,0)	0(0,2)	0(0,3)	1.5(0,3)	0(0,2)	0(0,3)	0(0,3)
OPAC (0–5)	2.5(0,5)	2(0,5)	3(0,5)	2(0,5)	3(0,5)	2(1,4)	2(0,5)	3(0,5)	3.5(3,4)	2(0,5)	2(0,5)	3.5(0,5)
MGI (0–3)	1(0,3)	2(0,3)	1.5(0,3)	1(0,3)	2(0,3)	1.5(1,2)	1(0,3)	1(0,3)	1.5(1,2)	1(0,3)	2(0,3)	1(0,3)
MCI (0–5)	2(0,5)	2(0,5)	2(1,5)	2(0,5)	2(0,5)	2(2,3)	2(0,5)	2(0,5)	2(1,3)	2(0,5)	2(0,4)	2.5(0,5)
PUNC (0–2)	2(0,2)	1(0,2)	2(0,2)	2(0,2)	2(0,2)	2(0,2)	2(0,2)	2(0,2)	2(2,2)	2(0,2)	2(0,2)	2(0,2)
HYPER (0–5)	1(0,5)	1(0,3)	1.5(0,5)	1(0,5)	1(0,5)	1(1,2)	1(0,5)	1(0,3)	1(0,2)	1(0,5)	1(0,3)	1(0,2)
CKERT (0–5)	0(0,5)	0(0,5)	0(0,5)	0(0,5)	0(0,5)	0(0,3)	0(0,5)	0(0,4)	3(3,3)*	0(0,5)	0(0,4)	1(0,4)
SYMB (0–5)	1(0,5)	0(0,4)	1(0,4)	1(0,5)	1(0,4)	0.5(0,1)	0.5(0,5)	1(0,4)	1.5(1,2)	1(0,5)	1(0,4)	2(0,4)

Number of patients with specific interleukin genotypes are shown column wise and the related graded ocular complications are shown row wise. Data are shown as median (min, max) values. Genotype-phenotype analysis revealed no significant link between IL-4, IL-4R, IL-13b genotypes and ocular complications except IL-13a genotypes for conjunctival keratinization (CKERT) where * shows ‘p’=0.004 as compared to CC and CT genotypes of IL-13a on Bonferroni correction. IL-4R,interleukin-4 receptor, IL-13a-interleukin-13 promoter region; IL-13b-interleukin-13 coding region; (0–5),severity score 0, 1,2,3,4,5; POV-loss of palisades of vogt; CONC- conjunctivalization; VASC-vascularization; KERT-keratinization; SPK-,superficial punctate keratopathy; OPAC-opacification; MGI-Meibomian gland involvement; MCI-mucocutaneous junction involvement; PUNC-punctal involvement; HYPER-Hyperemia; CKERT-conjunctival keratinization; SYMB-symblepharon formation.